Talk:Bevacizumab

From Wikipedia, the free encyclopedia

	This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess.
B	This page has been rated as B-Class on the quality assessment scale
Mid	This article has been rated as Mid-importance on the importance assessment scale

1 Mechanism
2 Bevacizumab Chemical Formula
3 Clinical Trials
4 Latest Information on the CATT Study of Avastin vs Lucentis for Wet AMD

[edit] Mechanism

It is now believed that Avastin does not block angiogenesis, but actually increases it. This then stabilises the tumour blood vessels, and allows other chemotherapy agents better access to the tumour site, increasing their efficacy. —Preceding unsigned comment added by 91.110.239.180 (talk) 12:08, 4 May 2008 (UTC)

[edit] Bevacizumab Chemical Formula

I am interested in the exact english version (name) la of Bevacizumab. So, if somebody knows it, I would appreciate his-her help! —Preceding unsigned comment added by 195.134.99.82 (talk)

The "zumab" part means humanized monoclonal antibody. The actual antibody may not have another name except for tradenames like Avastin and a sequence.Rbcody (talk) 13:23, 27 April 2008 (UTC)

[edit] Clinical Trials

I'd like some information on the clinical trials and success of Bevacizumab, or at least a link to some relevant scientific papers. Also, some information on the development of the drug would be useful. This is a much more interesting reference: http://www.wjgnet.com/1007-9327/13/5857.asp. It's a review on targeting angiogenesis as a treatment for cancer. —Preceding unsigned comment added by Sartchy (talk • contribs) 01:42, 21 November 2007 (UTC)